Global Antibody Drug Conjugate Market Size Study, by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), by Drugs (Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, Trodelvy), by Technology (Cleavable Linker, Linkerless, Non-Cleavable Linker), by Indicati

Global Antibody Drug Conjugate Market Size Study, by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), by Drugs (Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, Trodelvy), by Technology (Cleavable Linker, Linkerless, Non-Cleavable Linker), by Indication (Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, Urothelial Cancer & Bladder Cancer), by End User (Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, Specialized Cancer Centers) and Regional Forecasts 2022-2032

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030. The Antibody Drug Conjugate (ADC) Market involves the development, manufacturing, and commercialization of therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissues. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs is challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

The ADC market is experiencing a significant shift towards ErbB2 antibodies (HER2) due to their effectiveness in treating breast and gastric cancer. These ADCs have shown substantial clinical success in targeting the HER2 antigen, which is overexpressed in these cancers. Drugs like Enhertu have become prominent in the oncology field for their targeted therapies, providing improved patient outcomes. The preference for ErbB2 antibodies underscores the market's focus on precision medicine and targeted treatment approaches.

Technological advancements are also shaping the ADC market, with a rising preference for linkerless technology. This technology simplifies the manufacturing process and improves the stability and homogeneity of ADCs. Linkerless ADCs directly conjugate the cytotoxic drug to the antibody, offering streamlined production and potentially enhanced therapeutic efficacy. Additionally, cleavable and non-cleavable linkers continue to play crucial roles, with each offering unique benefits in terms of stability and targeted drug release.

In terms of indications, ADCs are rapidly gaining traction for treating breast cancer. Their ability to target overexpressed receptors, such as HER2, makes them highly effective in managing this prevalent cancer type. Furthermore, ADCs are extensively used for blood cancers, lymphomas, and multiple myeloma, demonstrating their versatility in oncology. These targeted therapies are revolutionizing cancer treatment, providing new hope for patients with previously limited options.

The end-user segment for ADCs is diverse, with significant adoption in academic research institutes, biopharmaceutical and biotechnology companies, hospitals, and specialized cancer centers. Academic research institutes are essential in advancing the understanding of ADC mechanisms and exploring new therapeutic applications. Biopharmaceutical and biotechnology companies are at the forefront of ADC development, investing heavily in R&D to discover novel targets and improve drug-linker technologies. Hospitals and specialized cancer centers play pivotal roles in validating ADC efficacy through clinical trials and integrating these innovative therapies into clinical practice.

The key regions considered for the global Antibody Drug Conjugate Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Antibody Drug Conjugate Market in terms of revenue. The market growth in the region is being attributed to factors including advancements in oncology and targeted therapies. The European Union (EU) maintains a robust regulatory framework for ADCs, fostering strategic collaborations and novel therapy developments. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D expenditure and the prevalence of cancer are propelling the need for ADCs. Additionally, the adoption of advanced technologies for manufacturing ADCs is anticipated to drive their utilization across end-use sectors.

Major market player included in this report are:

AbbVie Inc.

AstraZeneca PLC

Pfizer, Inc.

Roche Holding AG

GlaxoSmithKline PLC

Daiichi Sankyo Company, Limited

Seagen Inc.

ADC Therapeutics SA

ImmunoGen, Inc.

Astellas Pharma Inc.

Bayer AG

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Sorrento Therapeutics, Inc.

BioNTech SE

The detailed segments and sub-segment of the market are explained below:

By Mechanism of Action
• CD30 Antibodies
• ErbB2 Antibodies

By Drugs
• Adcetris
• Blenrep
• Enhertu
• Kadcyla
• Padcev
• Trodelvy

By Technology
• Cleavable Linker
• Linkerless
• Non-Cleavable Linker

By Indication
• Blood Cancer
• Breast Cancer
• Lymphoma
• Multiple Myeloma
• Urothelial Cancer & Bladder Cancer

By End User
• Academic Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Hospitals
• Specialized Cancer Centers

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.